Menu Search
Equities

AIM Vaccine Co Ltd

6660:HKG.HS

AIM Vaccine Co Ltd

Actions
  • Price (HKD)4.67
  • Today's Change-2.29 / -32.90%
  • Shares traded206.20k
  • 1 Year change-50.05%
  • Beta--
Data delayed at least 15 minutes, as of Aug 23 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year AIM Vaccine Co Ltd's revenues fell -6.06% from 1.26bn to 1.19bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 319.60m to a larger loss of 1.30bn.
Gross margin72.34%
Net profit margin-155.22%
Operating margin-174.42%
Return on assets-22.69%
Return on equity-29.05%
Return on investment-37.16%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at AIM Vaccine Co Ltd fell by 73.12m. Cash Flow from Financing totalled 362.07m or 30.49% of revenues. In addition the company used 165.50m for operations while cash used for investing totalled 271.96m.
Cash flow per share-1.47
Price/Cash flow per share--
Book value per share3.11
Tangible book value per share2.09
More ▼

Balance sheet in CNYView more

AIM Vaccine Co Ltd has a Debt to Total Capital ratio of 34.37%, a higher figure than the previous year's 14.21%.
Current ratio0.8512
Quick ratio0.6836
Total debt/total equity0.5596
Total debt/total capital0.3437
More ▼

Growth rates in CNY

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-126.02
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.